Prevalence and Clinicopathologic Characteristics of Hypercalcemia in Patients With Cholangiocarcinoma-Reference-Cited by-同舟云学术

Prevalence and Clinicopathologic Characteristics of Hypercalcemia in Patients With Cholangiocarcinoma

Published:2023-05-01 Issue:5 Volume:9 Page:714
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Konstantinidou Eirini¹,Maurer Jordan R.²,Reyes Stephanie L.²,Baiev Islam²,Stanton Jennifer R.²,Nipp Ryan D.²,Goyal Lipika²

Affiliation:

1. Cancer Center, Beth Israel Deaconess Medical Center, Division of Hematology-Oncology, Department of Medicine, Harvard Medical School, Boston, Massachusetts

2. Mass General Cancer Center, Division of Hematology and Oncology, Department of Medicine, Harvard Medical School, Boston, Massachusetts

Abstract

This cohort study investigates clinicopathologic and prognostic associations of hypercalcemia in patients with intrahepatic or extrahepatic cholangiocarcinoma.

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2802829/jamaoncology_konstantinidou_2023_ld_230001_1684353151.27192.pdf

Reference5 articles.

1. Prevalence of hypercalcemia among cancer patients in the United States.;Gastanaga;Cancer Med,2016

2. Cancer-associated hypercalcemia.;Guise;N Engl J Med,2022

3. Two cases of humoral hypercalcemia of malignancy in metastatic cholangiocarcinoma.;Lim;Cancer Res Treat,2013

4. Hypercalcemia of cancer in the digestive tract.;Monno;J Clin Gastroenterol,1987

5. US Food and Drug Administration. FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma. August 25, 2021. Accessed May 25, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case of Fibroblast Growth Factor Receptor Fusion-Positive Intrahepatic Cholangiocarcinoma With Humoral Hypercalcemia of Malignancy;Cureus;2024-04-22